文献速递血栓与止血

乳腺癌细胞介导内皮细胞活化,促进血管性血友病因子释放、肿瘤黏附及跨内皮迁移

Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration.
PubMed 文献 · J Thromb Haemost · 2022-07-10

研究探讨血管性血友病因子(VWF)在乳腺癌转移中的作用及低分子量肝素(LMWH)对内皮细胞活化和肿瘤跨内皮迁移的影响。转移性乳腺癌患者血浆VWF:Ag水平显著升高且与较差生存相关;乳腺癌细胞经VEGF-A促使内皮细胞分泌VWF、血管生成素-2和骨保护素,VWF多聚体介导肿瘤细胞黏附,LMWH可抑制该黏附与跨内皮迁移。

要点

  • 转移性乳腺癌患者血浆VWF:Ag水平显著升高,且与较差生存相关。
  • 乳腺癌细胞经VEGF-A促使内皮细胞分泌VWF、血管生成素-2和骨保护素,血小板可进一步增强。
  • LMWH抑制VWF介导的乳腺癌细胞黏附与跨内皮迁移。

核心结论

  • 肿瘤细胞与内皮细胞间存在显著交互作用,包括VWF分泌增加,可能促进肿瘤转移。

研究设计与样本

  • 实验研究:采用ELISA检测VWF水平,用原代内皮细胞评估肿瘤诱导的活化、血管生成、肿瘤黏附和跨内皮迁移。

主要发现

  • 转移性乳腺癌患者血浆VWF:Ag水平显著升高,且与较差生存相关。
  • MDA-MB-231和MCF-7乳腺癌细胞诱导内皮细胞分泌VWF、血管生成素-2和骨保护素,血小板存在时进一步增强。
  • VEGF-A在调控乳腺癌诱导的VWF释放中起重要作用,乳腺癌细胞来源VEGF-A对内皮细胞也有促血管生成作用。
  • 内皮细胞响应肿瘤VEGF-A分泌的VWF多聚体介导乳腺癌细胞沿内皮黏附。
  • LMWH抑制VWF-乳腺癌细胞黏附及跨内皮迁移。

关键数值与推荐

  • 转移性乳腺癌患者血浆VWF:Ag水平显著升高,原文未报告具体数值。
  • 乳腺癌患者静脉血栓栓塞风险增加三至四倍。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Breast cancer results in a three- to four-fold increased risk of venous thromboembolism (VTE), which is associated with reduced patient survival. Despite this, the mechanisms underpinning breast cancer-associated thrombosis remain poorly defined. Tumor cells can trigger endothelial cell (EC) activation resulting in increased von Willebrand factor (VWF) secretion. Importantly, elevated plasma VWF levels constitute an independent biomarker for VTE risk. Moreover, in a model of melanoma, treatment with low molecular weight heparin (LMWH) negatively regulated VWF secretion and attenuated tumor metastasis. OBJECTIVE: To investigate the role of VWF in breast cancer metastasis and examine the effect of LMWH in modulating EC activation and breast tumor transmigration. METHODS: von Willebrand factor levels were measured by ELISA. Primary ECs were used to assess tumor-induced activation, angiogenesis, tumor adhesion, and transendothelial migration. RESULTS AND CONCLUSION: Patients with metastatic breast cancer have markedly elevated plasma VWF:Ag levels that also correlate with poorer survival. MDA-MB-231 and MCF-7 breast cancer cells induce secretion of VWF, angiopoietin-2, and osteoprotegerin from ECs, which is further enhanced by the presence of platelets. Vascular endothelial growth factor-A (VEGF-A) plays an important role in modulating breast cancer-induced VWF release. Moreover, VEGF-A from breast tumor cells also contributes to a pro-angiogenic effect on ECs. VWF multimers secreted from ECs, in response to tumor-VEGF-A, mediate adhesion of breast tumor cells along the endothelium. LMWH inhibits VWF-breast tumor adhesion and transendothelial migration. Our findings highlight the significant crosstalk between tumor cells and the endothelium including increased VWF secretion which may contribute to tumor metastasis.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Dhami SPS, Patmore S, Comerford C, et al. Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration. J Thromb Haemost. 2022. PMID: 35722954. doi:10.1111/jth.15794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。